Navigation Links
Amira Pharmaceuticals to Present Preclinical Data on AM152 , an LPA1 Receptor Antagonist, at the Annual Meeting of the American Thoracic Society
Date:5/11/2011

SAN DIEGO, May 11, 2011 /PRNewswire/ -- Amira Pharmaceuticals, Inc. announced today that it will present preclinical data on AM152, an LPA1 receptor antagonist, during the Annual Meeting of the American Thoracic Society (ATS) in Denver, Colorado.  The poster, titled "The LPA1 Antagonist, AM152, Is Efficacious in Mouse Models of Fibrosis," will be presented on Monday, May 16, from 8:15 to 10:45 a.m. MDT.

The LPA1 receptor is part of the lysophosphatidic acid signaling pathway.  Under pathological conditions, LPA1 is associated with a breakdown of the endothelial barrier and the stimulation of fibroblast recruitment, proliferation and transformation, resulting in excessive deposition of extracellular matrix proteins.  Studies have shown that the LPA1 receptor may play a role in several fibrotic diseases, including Idiopathic Pulmonary Fibrosis (IPF).

"Our preclinical data demonstrate that AM152 reduces pro-fibrotic activity by fibroblasts in vitro and tissue fibrosis in numerous in vivo models," said Gretchen Bain, Ph.D., Executive Director of Biology.  "AM152 reduces fibrosis in multiple tissue types thus providing a strong rationale for clinical exploration in patients suffering from a variety of fibrotic diseases."

Bob Baltera, Chief Executive Officer, added, "Our lead LPA1 program, AM152, is one of the cornerstones for Amira's future.  As previously disclosed, we look forward to initiating Phase 2a clinical studies in patients suffering from fibrotic disease in order to explore the therapeutic benefit of this compound."

About Amira

Founded in 2005 and headquartered in San Diego, Amira Pharmaceuticals is a small molecule pharmaceutical company focused on the discovery and early development of new drugs to treat inflammatory and fibrotic diseases.  Amira combines the rigor of a big pharmaceutical company with the ingenuity and energy of a small company, creating an enviro
'/>"/>

SOURCE Amira Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Amira Pharmaceuticals Announces Completion of Phase 1 Clinical Study for AM152, A Novel LPA1 Receptor Antagonist
2. Amira Pharmaceuticals Receives Orphan Drug Status for a Novel LPA1 Antagonist, AM152, for the Treatment of Idiopathic Pulmonary Fibrosis
3. Amira Pharmaceuticals Announces the Nomination of an Orally Available Pre-Clinical Candidate in a New LPA-Related Program, an Autotaxin Inhibitor
4. Amira Pharmaceuticals Announces Initiation of Phase I Clinical Trial for AM152, A Novel LPA1 Antagonist
5. Amira Pharmaceuticals Announces IND Submission for Novel LPA1 Antagonist, AM152, for Potential Use in Fibrotic Diseases
6. Amira Pharmaceuticals Named One of Most Promising Biotech Companies by FierceBiotechs Annual Fierce 15
7. Visage Imaging Releases Amira 5.3
8. Amira Announces AM103 and AM803 Patent Grant in the United Kingdom
9. Amira Announces Second DP2 Antagonist Patent Grant in the United Kingdom
10. Anti-Fibrotic Data from Amira Pharmaceuticals LPA1 Receptor Antagonist Program Published in the British Journal of Pharmacology
11. Amira Pharmaceuticals Announces Efficacy of LPA1 Antagonist in a Preclinical Model of Scleroderma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 23, 2014   Assurex Health, ... support to healthcare providers for behavioral health and ... secured $30 million in equity financing from new ... Drosos , President and Chief Executive Officer. ... and development of Assurex Health,s GeneSight ® ...
(Date:12/24/2014)... Dec. 23, 2014 In response to urgent requests ... Sierra Leone , Direct Relief delivered two ... for the treatment of local health workers who contract Ebola ... dedicated Ebola care center was constructed for foreign health care ... not available for local Sierra Leonean health workers. ...
(Date:12/22/2014)... Mass. , Dec. 22, 2014 ... leading manufacturer of innovative dialysis products, announced today ... has cleared its System One™ to perform hemodialysis ... known as home nocturnal hemodialysis. NxStage,s® System One ... by the FDA for this indication. ...
Breaking Medicine Technology:Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 2Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 3Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 4First Ebola Treatment Unit for Local Health Workers Arrives in Sierra Leone 2NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 2NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 3
(Date:12/25/2014)... 25, 2014 When head lice hits a ... a frenzy to get rid of it while keeping it ... Coral Gables now have the solution right in their neighborhood: ... location, Lice Troopers provides full spectrum head lice screening and ... area, including Sunset, Key Biscayne, Brickell, Coconut Grove, Kendall, Pinecrest ...
(Date:12/25/2014)... 25, 2014 (HealthDay News) -- Overeating is common during the ... in moderation, an expert says. "Don,t arrive at a ... if you know you,ll be attending a party, but deprivation ... lead dietitian at Northern Westchester Hospital in Mount Kisco, N.Y., ... eat healthy during the day and even to have a ...
(Date:12/25/2014)... New York, New York (PRWEB) December 25, 2014 ... ) continue to move forward in a number ... Southern District of West Virginia, Bernstein Liebhard LLP reports. ... the Court is scheduled to convene a Joint Status ... 2015, at 10:00 a.m. Parties have been directed to ...
(Date:12/25/2014)... Each year trauma accounts for approximately 42 ... across the nation (according to the Centers for ... Hospital Ambulatory Medical Care Survey collected data from ... They estimated that there were between 3.5 and 4.4 ... diagnosis of broken bone or fracture. , When ...
(Date:12/24/2014)... Epigenetics finds applications in a large number of ... developmental biology, and research for metabolic and genetic disorders. ... widely used techniques for the discovery and development of ... is rapidly growing worldwide. In 2012, there were 14.1 ... 32.6 million people living with cancer (within five years ...
Breaking Medicine News(10 mins):Health News:Coral Gables Florida Gets Ready to Be Lice-Free with Lice Troopers 2Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 3Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 4Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 2Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 3Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 4Health News:Global Epigenetics Market Was Valued at $413.24 Million in 2014 - New Research Report by MarketsandMarkets 2Health News:Global Epigenetics Market Was Valued at $413.24 Million in 2014 - New Research Report by MarketsandMarkets 3
... the Ludwig Institute for Cancer Research at the University of ... step required for cell division in a study that could ... the mechanism of the contractile ring a structure that ... been published in the December 5 issue of the journal ...
... WASHINGTON, Dec. 9 McKenna Long & Aldridge ... Goldsmith, former two term Mayor of Indianapolis, is ... Partnerships (PPP) practice as a senior strategic advisor ... and infrastructure related issues in the transportation, energy, ...
... To Avoid Fiscal Crisis , , ... nine in ten hospital executives believe the current economic crisis will ... 2002, according to a survey released today by CSC (NYSE: ... Crisis." The impact is already being felt; 55 percent of ...
... that a total of,20 U.S. and global abstracts involving ... at the 2008 San Antonio,Breast Cancer Symposium (SABCS) in ... cancer to be presented on Sunday, December,14, by the ... Two U.S. abstracts to be presented at ...
... The following is being issued by ... Recently there has been a frenzy of articles in ... We are told there are 46 million,people without health insurance.(1) ... intervention with a nationalized healthcare,rescue plan passed within ninety days ...
... infrastructure and data center solutions, announced today the opening of their first ... UT. Voonami also announced two new adaptive computing data centers to ... data center will house up to 100,000 square feet with power capacity ... ...
Cached Medicine News:Health News:From mother to daughters: A central mystery in cell division solved 2Health News:Former Mayor of Indianapolis to Serve as a Senior Strategic Advisor to McKenna Long & Aldridge LLP's Global Infrastructure Finance and Public-Private Partnerships Practice 2Health News:CSC Survey Reveals Hospitals Find Current Recession Far Worse Than Last Downturn; Emergency Visits to Climb 2Health News:CSC Survey Reveals Hospitals Find Current Recession Far Worse Than Last Downturn; Emergency Visits to Climb 3Health News:Twenty New Abstracts on Oral Xeloda(R) (capecitabine) Featured at the 31st San Antonio Breast Cancer Symposium 2Health News:Twenty New Abstracts on Oral Xeloda(R) (capecitabine) Featured at the 31st San Antonio Breast Cancer Symposium 3Health News:Average Americans Without Health Insurance Are Young and Healthy With Above Average Incomes 2Health News:Voonami, Inc. Announces Three New Adaptive Data Centers 2
... Para 12 Plus is a hematology ... and 3500/3700. Assay values are provided for ... as a three-part differential on the CELL-DYN ... days and closed-vial stability is 75 days. ...
Indicated to facilitate the intra-luminal placement of conventional guidewires beyond stenotic lesions, including chronic total coronary occlusions....
... a whole blood hematology control manufactured specifically ... 120, and the Coulter AcT5diff instruments. The ... white cell differential, positioning the populations within ... systems. The product offers 105-day closed-vial stability ...
... is a spinal and body fluid control ... stained in the same manner as a ... be differentiated. The two-level control is assayed ... blood cell differential, as well as the ...
Medicine Products: